Medical News

RSS

Elekta receives EU CE marking for Connexion modular couchtop

Elekta's Connexion modular couchtop is CE marked and successfully released for sale in the European Union. Connexion meets the clinic's need to tailor patient set-up to accommodate the unique therapy requirements of the individual patient.

From Elekta 29 Mar 2012

Regulatory fight could turn ugly as Congress seeks to overhaul cosmetics regulations

In response to public pressure from recent scandals including mercury in face cream, lead in lipstick and formaldehyde in hair products, the House Energy and Commerce Health Subcommittee yesterday convened the first Congressional hearing in 30 years on the safety of cosmetics and personal care products.

29 Mar 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

Court wonders which parts of law -- if any -- can stand without the mandate

In exploring the severability question, the justices will ponder whether other parts of the health law can go forward if they void the individual mandate, considered the measure's central element. News outlets examine the "contingency plans" being explored by the law's supporters in case the mandate falls.

29 Mar 2012

BMI not associated with esophageal cancer patient survival

Researchers at Moffitt Cancer Center in Tampa, Fla., have found - contrary to previous studies linking inferior outcomes in patients with gastrointestinal malignancies to higher body mass index (BMI) - that in their study of BMI and negative outcomes, there was no such link. They concluded that BMI was not associated with either surgical complications or esophageal cancer patient survival.

29 Mar 2012

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 Mar 2012

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.

29 Mar 2012

FDA extends review period for Almirall and Forest Labs' aclidinium bromide NDA

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease.

29 Mar 2012

Nomir announces data from Noveon Laser pivotal trial on onychomycosis

Nomir Medical Technologies, Inc., a leader in novel photobiology and laser therapies, announced today that new data from its landmark pivotal onychomycosis trial first published in the peer-reviewed Journal of the American Podiatric Medical Association (JAPMA) has once again been published in this prestigious journal. The new paper, which reports on a 270 day onychomycosis clinical trial, offers further scientific support for using the Noveon lasers as an effective therapeutic treatment.

29 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

Minnesota Department of Health certifies ApeniMED as HDI

ApeniMED, a leader in healthcare interoperability and Nationwide Health Information Network (NwHIN) connectivity, today announced its certification as a Health Data Intermediary (HDI) by the Minnesota Department of Health.

29 Mar 2012

Ethiopia's workplace HIV/AIDS policy aims to help employers, employees nationwide

Ethiopia's new HIV/AIDS workplace policy, instituted in January by the government in cooperation with the country's main employees' and employers' associations, "is expected to protect job seekers from mandatory HIV tests, while facilitating voluntary counseling and testing and defending the right of employees living with HIV to medical leave or job re-allocation," PlusNews reports.

29 Mar 2012

anwerina, Ascendx Spine announce distribution partnership

Ascendx Spine, which recently received ISO 13485 Certification and CE marking approval for its Ascendx VCF Repair System and its Acu-Cut Vertebral Augmentation System to treat vertebral compression fractures (VCF), today announced an agreement with Switzerland-based anwerina AG to distribute the Ascendx Spine products in Austria, Germany and Switzerland.

29 Mar 2012

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

Vaccination for HPV reduces risk of renewed disease

The vaccination against human papillomavirus (HPV) reduces the risk of a renewed HPV-associated illness in patients who have already had diseases as a consequence of an HPV infection.

29 Mar 2012

Greenwood launches Syndromic Autism 62-Gene Panel

RainDance Technologies, Inc., the Digital Biology Company, today announced that Greenwood Genetic Center has commercially launched its Syndromic Autism 62-Gene Panel which was built for use on RainDance's picodroplet-based targeted sequencing platform.

29 Mar 2012

SafeStitch Medical's AMID Stapler to be presented at AHS 2012

SafeStitch Medical, Inc. will present the AMID Stapler® at the 5th International Hernia Congress in New York City, March 28-31, 2012.

29 Mar 2012

OncoSec Medical closes sale of 31,000,000 shares of common stock in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

New technique could restore fertility of boys undergoing cancer treatment

Treatments for childhood cancers are increasingly successful with cure rates approaching 80%, but success often comes with a downside for the surviving men: the cancer treatments they received as boys can leave them sterile as adults. Now, a research team led by Ralph Brinster of the University of Pennsylvania School of Veterinary Medicine has completed a 14-year experiment that gives hope for a technique that could restore their fertility.

29 Mar 2012